Filing Flows › Novartis AG (NVS) › R&D spending
Novartis AG (NVS) R&D spending by quarter
Novartis AG's R&D spending was $5.2B in Q3 2026 (third quarter 2026), +81% from Q2 2026. Over the last 5 quarters it ranged from $2.7B (Q2 2025) to $5.2B (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $5.2B | +81% | +75% |
| Q2 2026 | $2.8B | -10% | +4% |
| Q4 2025 | $3.2B | +7% | — |
| Q3 2025 | $2.9B | +8% | — |
| Q2 2025 | $2.7B | — | — |
Q3 2026 at a glance
Novartis AG, Q3 2026: revenue $14.5B (+4% year over year), operating margin 12.7%, net earnings $1.2B, operating cash flow $5.5B. The chart follows the revenue to costs, profit and cash.
Questions
What is Novartis AG's R&D spending?
Novartis AG's R&D spending was $5.2B in Q3 2026 (third quarter 2026), +81% from Q2 2026.
How has Novartis AG's R&D spending changed?
Over the last 5 quarters it ranged from $2.7B (Q2 2025) to $5.2B (Q3 2026).